BVF Partners filed an amended ownership report on Olema Pharmaceuticals

What did BVF Partners report?

In its Schedule 13D/A, BVF PARTNERS L P/IL reported 8,939,731 shares, representing 9.8% of the class of Olema Pharmaceuticals (OLMA). The filing was made on Oct 16, 2026.

A Schedule 13D or 13G is an ownership filing, not a trade report. This filing does not say when shares were bought.

How did the filing line up with company results?

The filing was made 65 days after Olema Pharmaceuticals announced results on Aug 10, 2026, in an 8-K under Item 2.02. The timing establishes the sequence of public records; it does not explain the reported ownership.

What other ownership records are available?

Fund 13F filings recorded in the 90 days to Oct 16, 2026 show 3 new or larger positions and 1 smaller or closed position in Olema Pharmaceuticals. For the quarter ended Jun 30, 2026, Paradigm Biocapital Advisors LP increased its position by 650,000 shares, and Siren, L.L.C. increased its position by 100,000 shares.

Erste Asset Management GmbH and Jennison Associates LLC sold out. A 13F is a quarter-end snapshot with no trade date, so it does not show when a reported position changed.

What company and market records were reported around the filing?

Olema Pharmaceuticals filed a Form 8-K of Oct 15, 2026, one day after the ownership filing. The report concerned a change involving a top executive or board member. The company’s opening sentence says: “On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the 'Company') of his decision to resign from the Company’s Board of Directors (the 'Board'), effective October 14, 2026.”

OLMA closed at $6.80 on Oct 14, 2026, the last session on or before the filing date. From Sep 14, 2026 to Oct 14, 2026, the close moved from $10.29 to $6.80, a change of −33.9%. These price moves are context only; the filing does not explain them, and other news can move a price.

What do clinical-trial and short-interest records show?

ClinicalTrials.gov shows 2 studies sponsored by the company updated in the period. The latest, Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer, is a Phase 3 study with status recruiting. It was updated on Sep 23, 2026, and primary completion is listed for 2028-12.

FINRA short interest for OLMA on the settlement date of Sep 30, 2026 was 14,696,219 shares, down -8.54% on the previous report, or about 10.19 days of average volume.

What this does not tell you?

The ownership filing does not say when shares were bought. The company’s 8-K reports what the company disclosed, not what that disclosure means for the share price. The listed price moves do not establish what caused them, and other news can move a price.

This article describes public filings and records. It is not investment advice. See Olema Pharmaceuticals on OQRO for the company’s public-record context.